The reiteration of an Overweight rating and a high price target by a reputable analyst like Louise Chen from Cantor Fitzgerald could positively influence investor sentiment towards Novo Nordisk. This endorsement reaffirms the company's strong position in the market and potential for future growth, likely leading to increased investor confidence and a positive short-term impact on the stock price.